Clinical Trial Update: Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating cerebrospinal fluid immune microenvironment mechanisms in ALK-positive non-small cell lung cancer. The study status is not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: NOT_YET_RECRUITING